Blood soluble Fas concentrations and ischemic stroke patient mortality

Expert Rev Mol Diagn. 2022 Dec;22(12):1117-1121. doi: 10.1080/14737159.2022.2165913. Epub 2023 Jan 9.

Abstract

Background: Fas is a major receptor for cell death by apoptosis. Higher blood concentrations of soluble Fas (sFas) have been reported in patients with ischemic stroke compared to control subjects. The aim of this study was to explore the existence or not of an association between blood sFas concentrations and mortality in patients with ischemic stroke.

Methods: This study included patients admitted to Intensive Care Units with severe and malignant middle cerebral artery infarction (MCAI), defined as acute infarction, in more than 50% of this territory on computed tomography and less than 9 points on the Glasgow Coma Scale (GCS). Serum sFas levels were determined at the time of diagnosis of MMCAI.

Results: Non-surviving severe MMCAI patients (n = 27) showed lower platelet count (p = 0.004), higher serum sFas (p < 0.001), and lower GCS (p = 0.001) compared to surviving patients (n = 27). Multiple logistic regression found an association of serum sFas levels and mortality at 30 days (OR = 1.015; 95% CI = 1.002-1.027; p = 0.02) after control for CGS and platelet count.

Conclusions: The main novelty of our study was the existence of an association between high blood sFas concentrations and mortality in patients with ischemic stroke.

Keywords: cerebral infarction; mortality; patients; sFas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Glasgow Coma Scale
  • Humans
  • Infarction, Middle Cerebral Artery / pathology
  • Ischemic Stroke*
  • Prospective Studies

Substances

  • FAS protein, human